It will behoove drug makers to anticipate real world efficacy prior to launch, as the limiting factor for commercialization could soon be not whether a drug is approved by the FDA, based on clinical trial data, but whether it’s validated by clinical data companies, based on real-world performance.
from Forbes Real Time https://www.forbes.com/sites/davidshaywitz/2018/03/09/beyond-flatiron-the-rising-power-of-oncology-clinical-data-companies/
via IFTTT
No comments:
Post a Comment